Tag: krogsgaard
-
Novo plans larger study after encouraging semaglutide results
By Nikolaj Skydsgaard COPENHAGEN (Reuters) – Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, according to results released on Friday, paving the way for a new and bigger study on the drug's benefits. Semaglutide is the third diabetes drug to show such heart benefits, after Novo's Victoza injectable and Eli…